Jean-Marc Sabaté
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jean-Marc Sabaté has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Robert Benamouzig
Avicenne Hospital
9 shared publications - Michel Bouchoucha
Department of Gastroenterology, Hôpital Avicenne, Bobigny, France
7 shared publications - Chantal Julia
Université Sorbonne Paris Nord and Université Paris Cité, INSERM, INRAE, CNAM, Centre for Research in Epidemiology and StatisticS (CRESS), Nutritional Epidemiology Research Team (EREN), Bobigny, France
4 shared publications - Serge Hercberg
Université Sorbonne Paris Nord and Université Paris Cité, INSERM, INRAE, CNAM, Centre for Research in Epidemiology and StatisticS (CRESS), Nutritional Epidemiology Research Team (EREN) , 74 rue Marcel Cachin, 93017 Bobigny, Seine-Saint-Denis
4 shared publications - Fabien Wuestenberghs
Department of Gastroenterology and Digestive Oncology, Hôpital Avicenne, AP‐HP Sorbonne Paris Nord University Bobigny France
3 shared publications - Mathilde Touvier
Université Sorbonne Paris Nord and Université Paris Cité, INSERM, INRAE, CNAM, Center of Research in Epidemiology and StatisticS (CRESS), Nutritional Epidemiology Research Team (EREN), Bobigny, France
3 shared publications
Latest Publications
- 8 April 2026
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (4) , e70308
Impact of Early‐Onset IBS on Schooling, Illness in Adulthood, and Career Prospects
Introduction: Irritable bowel syndrome (IBS) is a disorder of gut–brain interaction that significantly affects patients' quality of life, particularly in educational and professional settings. This study aimed to assess the impact of IBS on schooling, higher education, and future professional life. Methods: An online survey was conducted among members of a French patient association and visitors to its website. Adult participants provided demographic data, details on disease severity, and feedback on their educational and professional experiences. Results: Among 365 participants with IBS, 42% reported having IBS during their schooling or higher education. The most commonly reported difficulties included restricted access to toilets during class (40%), problems with school‐provided meals (39%), and lack of privacy in restrooms (50%). Additionally, 62% of the participants reported that IBS had a direct negative impact on their academic performance, leading to frequent late arrivals at class (59%), absenteeism (70%), and repeating a year (23%). Irritable bowel syndrome was rarely addressed in academic settings (27%), though 52% of adaptation requests were granted. Finally, IBS was associated with lower income levels and reduced career prospects compared with individuals without IBS during their education ( p < 0.005). Conclusion: Irritable bowel syndrome has a significant impact on schooling and career development. Greater awareness and recognition of this condition in educational and professional environments are necessary to improve affected individuals' quality of life and professional integration.
- 8 April 2026
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (4) , e70308
Impact of Early‐Onset IBS on Schooling, Illness in Adulthood, and Career Prospects
Introduction: Irritable bowel syndrome (IBS) is a disorder of gut–brain interaction that significantly affects patients' quality of life, particularly in educational and professional settings. This study aimed to assess the impact of IBS on schooling, higher education, and future professional life. Methods: An online survey was conducted among members of a French patient association and visitors to its website. Adult participants provided demographic data, details on disease severity, and feedback on their educational and professional experiences. Results: Among 365 participants with IBS, 42% reported having IBS during their schooling or higher education. The most commonly reported difficulties included restricted access to toilets during class (40%), problems with school‐provided meals (39%), and lack of privacy in restrooms (50%). Additionally, 62% of the participants reported that IBS had a direct negative impact on their academic performance, leading to frequent late arrivals at class (59%), absenteeism (70%), and repeating a year (23%). Irritable bowel syndrome was rarely addressed in academic settings (27%), though 52% of adaptation requests were granted. Finally, IBS was associated with lower income levels and reduced career prospects compared with individuals without IBS during their education ( p < 0.005). Conclusion: Irritable bowel syndrome has a significant impact on schooling and career development. Greater awareness and recognition of this condition in educational and professional environments are necessary to improve affected individuals' quality of life and professional integration.
- 27 March 2026
- Published by Elsevier in Journal of Gynecology Obstetrics and Human Reproduction
- Vol. 55 (6) , 103167
Consensus-based management of endometriosis-associated pelvic pain: Results of a French Delphi study
- 27 March 2026
- Published by Elsevier in Journal of Gynecology Obstetrics and Human Reproduction
- Vol. 55 (6) , 103167
Consensus-based management of endometriosis-associated pelvic pain: Results of a French Delphi study
- Open Access
- 1 September 2025
- Published by Taylor & Francis in Clinical and Experimental Gastroenterology
- Vol. ume 18, 205-213
Panenteric Capsule Endoscopy in Young Patients with Suspected Irritable Bowel Syndrome: A Self-Controlled Feasibility Study
Objective: Although the diagnosis of irritable bowel syndrome (IBS) is based on clinical criteria, a colonoscopy is often performed to rule out alternative digestive disorders. The panenteric PillCam™ Crohn’s capsule, which allows non-invasive examination of both the small bowel and the colon, may be an alternative investigation. We aimed to evaluate the feasibility of a strategy based on the panenteric capsule in combination with standard biological tests to exclude gastrointestinal disease in young adult patients with chronic abdominal symptoms suggestive of IBS as an alternative to the classical approach based on colonoscopy. Design: Of 42 consecutive adults aged 18– 50 years with symptoms consistent with IBS for more than 6 months, 33 were enrolled, and 27 received both routine biological tests, fecal calprotectin, panenteric capsule, and gastrointestinal endoscopies. Results: All 21 lesions identified by the capsule in 15 patients were unrelated to digestive symptoms, as were the 11 lesions identified by colonoscopy in 7 patients, and all were of little or no clinical interest. In addition, one gastric ulcer and one gastric MALT lymphoma diagnosed only by systematic gastric biopsy were characterized by upper endoscopy. The capsule was preferred by all patients to the classical endoscopic procedures. Conclusion: The diagnosis of IBS was not called into question in any of the patients explored. These preliminary results demonstrate the feasibility of a strategy based on the panenteric capsule in combination with standard biological tests to exclude gastrointestinal disease in young adult patients with chronic abdominal symptoms suggestive of IBS. Plain Language Summary: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction characterized by abdominal pain and altered bowel transit without structural lesions explaining the symptoms. A diagnosis of IBS is clinical, but a colonoscopy can exclude other bowel disorders. Panenteric capsule endoscopy, an alternative to colonoscopy, noninvasively examines the small bowel and colon. We aimed to evaluate the feasibility of a strategy based on the panenteric capsule in combination with standard biological tests to exclude other gastrointestinal diseases in young adult patients with chronic abdominal symptoms suggestive of IBS as an alternative to the classical approach based on colonoscopy. Our study shows that the use of pancapsule in young adults with IBS symptoms is feasible, with all patients preferring the pancapsule over colonoscopy, indicating higher acceptability. Furthermore, lesions found by capsule and colonoscopy were unrelated to symptoms, and the IBS diagnosis remained unchanged, suggesting that the pancapsule was sufficient. In conclusion, pancapsule endoscopy could be a feasible alternative to colonoscopy for young adults with suspected IBS.
- 1 September 2025
- Published by Taylor & Francis in Clinical and Experimental Gastroenterology
- Vol. ume 18, 205-213
Open AccessPanenteric Capsule Endoscopy in Young Patients with Suspected Irritable Bowel Syndrome: A Self-Controlled Feasibility Study
Objective: Although the diagnosis of irritable bowel syndrome (IBS) is based on clinical criteria, a colonoscopy is often performed to rule out alternative digestive disorders. The panenteric PillCam™ Crohn’s capsule, which allows non-invasive examination of both the small bowel and the colon, may be an alternative investigation. We aimed to evaluate the feasibility of a strategy based on the panenteric capsule in combination with standard biological tests to exclude gastrointestinal disease in young adult patients with chronic abdominal symptoms suggestive of IBS as an alternative to the classical approach based on colonoscopy. Design: Of 42 consecutive adults aged 18– 50 years with symptoms consistent with IBS for more than 6 months, 33 were enrolled, and 27 received both routine biological tests, fecal calprotectin, panenteric capsule, and gastrointestinal endoscopies. Results: All 21 lesions identified by the capsule in 15 patients were unrelated to digestive symptoms, as were the 11 lesions identified by colonoscopy in 7 patients, and all were of little or no clinical interest. In addition, one gastric ulcer and one gastric MALT lymphoma diagnosed only by systematic gastric biopsy were characterized by upper endoscopy. The capsule was preferred by all patients to the classical endoscopic procedures. Conclusion: The diagnosis of IBS was not called into question in any of the patients explored. These preliminary results demonstrate the feasibility of a strategy based on the panenteric capsule in combination with standard biological tests to exclude gastrointestinal disease in young adult patients with chronic abdominal symptoms suggestive of IBS. Plain Language Summary: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction characterized by abdominal pain and altered bowel transit without structural lesions explaining the symptoms. A diagnosis of IBS is clinical, but a colonoscopy can exclude other bowel disorders. Panenteric capsule endoscopy, an alternative to colonoscopy, noninvasively examines the small bowel and colon. We aimed to evaluate the feasibility of a strategy based on the panenteric capsule in combination with standard biological tests to exclude other gastrointestinal diseases in young adult patients with chronic abdominal symptoms suggestive of IBS as an alternative to the classical approach based on colonoscopy. Our study shows that the use of pancapsule in young adults with IBS symptoms is feasible, with all patients preferring the pancapsule over colonoscopy, indicating higher acceptability. Furthermore, lesions found by capsule and colonoscopy were unrelated to symptoms, and the IBS diagnosis remained unchanged, suggesting that the pancapsule was sufficient. In conclusion, pancapsule endoscopy could be a feasible alternative to colonoscopy for young adults with suspected IBS.
- 9 June 2025
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 53 (11) , 536-547
Douleurs pelviennes associées à l’endométriose, conseils pour la pratique clinique. Un consensus formalisé d’experts par le CNGOF & Convergences PP
- 9 June 2025
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 53 (11) , 536-547
Douleurs pelviennes associées à l’endométriose, conseils pour la pratique clinique. Un consensus formalisé d’experts par le CNGOF & Convergences PP
- Open Access
Naloxegol for the Treatment of Opioid-Induced Constipation in Patients with Cancer Pain: A Pooled Analysis of Real-World Data
Objective: The aim of the NALOPOOL project was to assess the efficacy and safety of naloxegol in patients with cancer pain who exhibited opioid-induced constipation (OIC) and were treated under real-world conditions. Methods: We pooled individual patient data from three multicenter observational studies conducted with naloxegol in patients with cancer who exhibited OIC and were prescribed naloxegol under real-world conditions. Efficacy outcomes were evaluated after 4 weeks of treatment. All analyses were performed via a visit-wise approach. Heterogeneity was assessed via Cochran’s Q-test or Levene’s test. Results: Spontaneous bowel movements (SBM) response (≥3 SBM per week and an increase of ≥1 from baseline; three studies) was reported in 223 of 314 evaluable patients (71%, 95% CI 66–76); clinically relevant improvement in the Patient Assessment of Constipation Quality-of-Life Questionnaire (>0.5 points; three studies) occurred in 179 of 299 evaluable patients (60%, 95% CI 56–74) and in the Patient Assessment of Constipation Symptoms (>0.5 points; two studies) was reported in 131 of 190 evaluable patients (69%, 95% CI 62–76); and clinically relevant improvement in the Bowel Function Index (score ≥ 12 points at the endpoint; two studies;) was reported in 133 of 195 evaluable patients (68%, 95% CI 62–75). No significant heterogeneity was found for any efficacy outcome. The pooled proportion of patients who discontinued the drug owing to adverse reactions was 6.1% (95% CI 3.8% to 8.4%). Conclusions: Our results support the use of naloxegol for the management of OIC in patients with cancer pain who do not respond to laxative treatment.
Open AccessNaloxegol for the Treatment of Opioid-Induced Constipation in Patients with Cancer Pain: A Pooled Analysis of Real-World Data
Objective: The aim of the NALOPOOL project was to assess the efficacy and safety of naloxegol in patients with cancer pain who exhibited opioid-induced constipation (OIC) and were treated under real-world conditions. Methods: We pooled individual patient data from three multicenter observational studies conducted with naloxegol in patients with cancer who exhibited OIC and were prescribed naloxegol under real-world conditions. Efficacy outcomes were evaluated after 4 weeks of treatment. All analyses were performed via a visit-wise approach. Heterogeneity was assessed via Cochran’s Q-test or Levene’s test. Results: Spontaneous bowel movements (SBM) response (≥3 SBM per week and an increase of ≥1 from baseline; three studies) was reported in 223 of 314 evaluable patients (71%, 95% CI 66–76); clinically relevant improvement in the Patient Assessment of Constipation Quality-of-Life Questionnaire (>0.5 points; three studies) occurred in 179 of 299 evaluable patients (60%, 95% CI 56–74) and in the Patient Assessment of Constipation Symptoms (>0.5 points; two studies) was reported in 131 of 190 evaluable patients (69%, 95% CI 62–76); and clinically relevant improvement in the Bowel Function Index (score ≥ 12 points at the endpoint; two studies;) was reported in 133 of 195 evaluable patients (68%, 95% CI 62–75). No significant heterogeneity was found for any efficacy outcome. The pooled proportion of patients who discontinued the drug owing to adverse reactions was 6.1% (95% CI 3.8% to 8.4%). Conclusions: Our results support the use of naloxegol for the management of OIC in patients with cancer pain who do not respond to laxative treatment.
- Open Access
- 23 February 2025
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 7 (1) , 19
Efficacy and Safety of Chia Seed Powder, Pea Protein, and Xyloglucan in Patients with Constipation-Predominant Irritable Bowel Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
Background/Objectives: Natural compounds represent novel promising alternative treatments for functional gastrointestinal disorders. This multicenter, double-blind, randomized, placebo-controlled, crossover study aimed to evaluate the efficacy and safety of xyloglucan, pea protein, and chia seed powder (XP + CS) in irritable bowel syndrome with constipation (IBS-C). Methods: Sixty patients received twice-daily XP + CS or placebo for 28 days. Following a 28-day washout period, patients switched to the alternative treatment for another 28 days. Efficacy was evaluated using the Bristol Stool Form Scale; a seven-point Likert scale for abdominal pain, bloating, and discomfort; a Visual Analogue Scale for IBS symptom severity; the quality of life (QoL)-IBS questionnaire; Sickness Impact Profile (SIP) score; and serum zonulin concentrations. Adverse events were monitored throughout the study. Results: Compared to the placebo, XP + CS significantly improved stool consistency (p = 0.04 and p < 0.001 at days 15 and 28, respectively), IBS symptoms (p < 0.001 at day 15), QoL (p < 0.001 from day 15 on), and nearly all SIP domains (p < 0.001 at all time-points). Additionally, XP + CS treatment restored serum zonulin concentrations to within normal ranges by day 15. No serious adverse events were reported. Conclusions: This study provides evidence supporting the efficacy and safety of XP + CS in managing IBS-C symptoms.
- 23 February 2025
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 7 (1) , 19
Open AccessEfficacy and Safety of Chia Seed Powder, Pea Protein, and Xyloglucan in Patients with Constipation-Predominant Irritable Bowel Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
Background/Objectives: Natural compounds represent novel promising alternative treatments for functional gastrointestinal disorders. This multicenter, double-blind, randomized, placebo-controlled, crossover study aimed to evaluate the efficacy and safety of xyloglucan, pea protein, and chia seed powder (XP + CS) in irritable bowel syndrome with constipation (IBS-C). Methods: Sixty patients received twice-daily XP + CS or placebo for 28 days. Following a 28-day washout period, patients switched to the alternative treatment for another 28 days. Efficacy was evaluated using the Bristol Stool Form Scale; a seven-point Likert scale for abdominal pain, bloating, and discomfort; a Visual Analogue Scale for IBS symptom severity; the quality of life (QoL)-IBS questionnaire; Sickness Impact Profile (SIP) score; and serum zonulin concentrations. Adverse events were monitored throughout the study. Results: Compared to the placebo, XP + CS significantly improved stool consistency (p = 0.04 and p < 0.001 at days 15 and 28, respectively), IBS symptoms (p < 0.001 at day 15), QoL (p < 0.001 from day 15 on), and nearly all SIP domains (p < 0.001 at all time-points). Additionally, XP + CS treatment restored serum zonulin concentrations to within normal ranges by day 15. No serious adverse events were reported. Conclusions: This study provides evidence supporting the efficacy and safety of XP + CS in managing IBS-C symptoms.
- Open Access
- 30 January 2024
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 30 (1) , 97-105
Relationship Between Colonic Transit Response to Eating With Self-reported Constipation Severity in Constipated Patients According to the Phenotype
David Deutsch, Michel Bouchoucha, Julien Uzan, Gheorghe Airinei, Jean-Marc Sabate, and Robert Benamouzig. J Neurogastroenterol Motil 2024;30:97-105. https://doi.org/10.5056/jnm21091
- 30 January 2024
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 30 (1) , 97-105
Open AccessRelationship Between Colonic Transit Response to Eating With Self-reported Constipation Severity in Constipated Patients According to the Phenotype
David Deutsch, Michel Bouchoucha, Julien Uzan, Gheorghe Airinei, Jean-Marc Sabate, and Robert Benamouzig. J Neurogastroenterol Motil 2024;30:97-105. https://doi.org/10.5056/jnm21091
- 1 December 2023
- Published by JLE in Hépato-Gastro & Oncologie Digestive
- Vol. 30 (10) , 1067-1073
Functional dyspepsia – what’s new in pathophysiology, how to diagnose and manage it?
- 1 December 2023
- Published by JLE in Hépato-Gastro & Oncologie Digestive
- Vol. 30 (10) , 1067-1073
Functional dyspepsia – what’s new in pathophysiology, how to diagnose and manage it?
- Open Access
- 21 February 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 28 (7) , 732-744
Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome
Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome
- 21 February 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 28 (7) , 732-744
Open AccessEffect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome
Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome
- Open Access
Fermentable Oligo-, Di-, and Mono-Saccharides and Polyols (FODMAPs) Consumption and Irritable Bowel Syndrome in the French NutriNet-Santé Cohort
(1) Background: Specific foods, and more particularly, fermentable oligo-, di-, and mono-saccharides and polyols (FODMAPs) are often considered as triggers of digestive symptoms in Irritable Bowel Syndrome (IBS). Our aim was to study FODMAP consumption in controls and IBS participants in a large French population-based cohort; (2) Methods: Participants from the NutriNet-Santé cohort study completed the Rome IV and IBS-SSS questionnaire in a cross sectional study. Among them, 27,949 eligible participants had previously completed three 24-h recalls as well as anthropometrics, socio-demographical and lifestyle data. Total FODMAP intake (in g/day) was computed using a specific composition table. The association between FODMAPs and IBS was estimated through multivariable logistic regression models; (3) Results: Included participants were mainly women (75.4%) and the mean age was 43.4 ± 14.1 years. FODMAPs accounted for a mean daily intake of 19.4 ± 9.5 g/day. Overall 1295 participants (4.6%) were identified with an IBS. After adjusting for confounding factors, IBS participants had lower intakes in FODMAPs than non-IBS ones (aOR: 0.88, 95% CI: 0.82–0.95, p-value: 0.001). IBS severity was associated with more frequent low FODMAP intakes (<9 g/day); (4) Conclusions: Participants tended to consume 19 g of FODMAPs per day, but slightly less for IBS participants than for controls. In IBS participants, higher severity was associated with lower intakes.
Open AccessFermentable Oligo-, Di-, and Mono-Saccharides and Polyols (FODMAPs) Consumption and Irritable Bowel Syndrome in the French NutriNet-Santé Cohort
(1) Background: Specific foods, and more particularly, fermentable oligo-, di-, and mono-saccharides and polyols (FODMAPs) are often considered as triggers of digestive symptoms in Irritable Bowel Syndrome (IBS). Our aim was to study FODMAP consumption in controls and IBS participants in a large French population-based cohort; (2) Methods: Participants from the NutriNet-Santé cohort study completed the Rome IV and IBS-SSS questionnaire in a cross sectional study. Among them, 27,949 eligible participants had previously completed three 24-h recalls as well as anthropometrics, socio-demographical and lifestyle data. Total FODMAP intake (in g/day) was computed using a specific composition table. The association between FODMAPs and IBS was estimated through multivariable logistic regression models; (3) Results: Included participants were mainly women (75.4%) and the mean age was 43.4 ± 14.1 years. FODMAPs accounted for a mean daily intake of 19.4 ± 9.5 g/day. Overall 1295 participants (4.6%) were identified with an IBS. After adjusting for confounding factors, IBS participants had lower intakes in FODMAPs than non-IBS ones (aOR: 0.88, 95% CI: 0.82–0.95, p-value: 0.001). IBS severity was associated with more frequent low FODMAP intakes (<9 g/day); (4) Conclusions: Participants tended to consume 19 g of FODMAPs per day, but slightly less for IBS participants than for controls. In IBS participants, higher severity was associated with lower intakes.